INCY Quote, Trading Chart, Incyte Corporation

$86.13 Last:

1.17% Change Percent:

$85.41 Open:

$86.13 Previous Close:

$86.53 High:

$84.42 Low:

1,394,675 Volume:

06/24/2021 04:42:01 am Last Trade Date Time:

Quotes are delayed by 15 to 20 minutes.

Stock Date	Open Price	Close Price	High	Low	Volume
2021-06-24	85.41	86.13	86.53	84.42	1,394,675
2021-06-23	85.5	85.13	85.7479	84.31	1,200,832
2021-06-22	85.15	85.09	85.99	82.44	2,126,601
2021-06-21	84.42	84.93	85.18	84.0901	1,450,874
2021-06-18	83	83.96	84.14	82.62	2,069,639
2021-06-17	82.88	83.13	83.58	82	1,451,069
2021-06-16	82.91	83.12	84.08	82.27	2,048,730
2021-06-15	82.55	82.76	83.28	82.26	1,510,493
2021-06-14	82.94	82.64	83.28	81.04	1,437,451
2021-06-11	84.67	82.58	85	81.06	2,673,680
2021-06-10	86.38	87.53	87.65	85.635	893,497
2021-06-09	84.77	86.2	86.34	84.69	952,214
2021-06-08	85.88	84.645	86.3	83.97	657,713
2021-06-07	83.48	85.11	85.79	83.04	1,175,052
2021-06-04	83.17	83.33	84.45	82.86	1,015,417
2021-06-03	82.44	82.9	83.12	81.46	1,004,414
2021-06-02	82.87	82.26	83.37	82	969,093
2021-06-01	84.13	82.89	84.41	82.39	937,768
2021-05-31	83.435	83.78	84.2259	82.61	956,241
2021-05-28	83.435	83.78	84.2259	82.61	946,281

Stock Information

Incyte Corporation Company Name:

INCY Stock Symbol:

NASDAQ Market:

Incyte Corporation Website:

INCY Quote, Trading Chart, Incyte Corporation

Get INCY Alerts

News, Short Squeeze, Breakout and More Instantly...

INCY - Incyte Announces Outcome of FDA Oncologic Drugs Advisory Committee (ODAC) Meeting Reviewing Retifanlimab as a Treatment for Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)

Incyte (Nasdaq:INCY) today announced the outcome of a meeting of the Oncologic Drugs Advisory Committee (ODAC) of the U.S. Food and Drug Administration (FDA), which reviewed the Biologics License Application (BLA) for retifanlimab, an intravenous PD-1 inhibitor, as a potential treatment...
INCY - How This Pharma Company Can Benefit From Its Competitors

The race is on among pharmaceutical companies to obtain approval from the U.S. Food and Drug Administration (FDA) for new products serving the atopic dermatitis (AD, otherwise known as severe and chronic eczema) market. One of those companies, Incyte (NASDAQ: INCY) , is coming off s...
INCY - Incyte Announces Updated Data for Ruxolitinib Cream Accepted for Presentation at the 2021 Revolutionizing Atopic Dermatitis (RAD) Virtual Conference

-- First presentation of long-term safety and disease control data from Phase 3 TRuE-AD studies of ruxolitinib cream in atopic dermatitis Incyte (Nasdaq:INCY) today announced that multiple abstracts highlighting updated data for ruxolitinib cream, an investigational topical ...